Abstract

MUCORMYCOSIS: A SYSTEMATIC REVIEW

Shubham Sharma*, Jobanpreet Kaur, Ravi Kumar, Varun Kumar, Sonia Kaur and Khushmeen Kaur

ABSTRACT

Mucormycosis refers to any fungal infection produced by Mucorales fungus. Mucormycetes are classified as order Mucorales in the Mucoromycotina subphylum. Mucormycosis rhinocerebral (sinus and brain) is a sinus infection that can migrate to the brain. Mucormycosis is the most common in patients who have uncontrolled diabetes or who have undergone a kidney transplant. Hyphae developing in and around blood vessels is a common symptom of the illness, which can be life-threatening in diabetics or those who are severely immunocompromised. On the other hand, Zygomycota has been determined to be polyphyletic and is not included in the contemporary fungal classification. The disease is also known as a black fungus. Antifungal medications are used in conjunction with surgical intervention in the treatment of fungal infections. Isavuconazole, the sole novel drug with action against Mucorales, was recently FDA authorized to treat invasive aspergillosis and invasive mucormycosis. Mucormycosis epidemiology has changed in recent years due to an increase in prevalence, new causative agents, and a vulnerable population. The growth has been noticed throughout the world, but it is the most noticeable on the Asian continent. In Asia, diabetes mellitus still outnumbers all other risk factors, although post-tuberculosis and chronic renal failure are emerging as new risk categories. This review highlights the overview of Mucormycosis with treatment.

Keywords: Mucormycosis, Zygomycosis, Pathogenesis, Rhinocerebral, Diabetes mellitus, Aspergillosis.